Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $12.63 Consensus Target Price from Analysts

Posted by Stanley Muller on May 15th, 2026

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) has been assigned a consensus recommendation of “Buy” from the nine analysts that are currently covering the firm, Marketbeat Ratings reports. Eight research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $12.6250.

A number of brokerages have recently weighed in on CATX. BTIG Research restated a “buy” rating and issued a $14.00 target price on shares of Perspective Therapeutics in a research note on Tuesday, March 17th. UBS Group upped their price objective on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, March 18th. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Tuesday, May 5th. Piper Sandler assumed coverage on Perspective Therapeutics in a research note on Thursday, February 19th. They issued an “overweight” rating and a $16.00 price objective on the stock. Finally, Royal Bank Of Canada dropped their price objective on Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, March 17th.

Check Out Our Latest Stock Report on Perspective Therapeutics

Perspective Therapeutics Price Performance

CATX stock opened at $3.86 on Friday. The stock has a 50-day moving average price of $4.41 and a 200-day moving average price of $3.60. Perspective Therapeutics has a 1-year low of $1.96 and a 1-year high of $6.16.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last issued its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.04. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. As a group, equities research analysts forecast that Perspective Therapeutics will post -1.15 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in Perspective Therapeutics by 15.8% in the second quarter. Geode Capital Management LLC now owns 1,382,814 shares of the company’s stock valued at $4,758,000 after acquiring an additional 188,887 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Perspective Therapeutics by 118.4% in the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after acquiring an additional 405,612 shares during the last quarter. Walleye Capital LLC increased its stake in Perspective Therapeutics by 375.8% in the second quarter. Walleye Capital LLC now owns 187,403 shares of the company’s stock valued at $645,000 after acquiring an additional 148,013 shares during the last quarter. Federated Hermes Inc. increased its stake in Perspective Therapeutics by 44.4% in the second quarter. Federated Hermes Inc. now owns 195,080 shares of the company’s stock valued at $671,000 after acquiring an additional 60,019 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Perspective Therapeutics by 8.5% in the second quarter. Bank of America Corp DE now owns 327,500 shares of the company’s stock valued at $1,127,000 after acquiring an additional 25,697 shares during the last quarter. Institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.